MARY J STATES

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care SAN DIEGO, CA NPI 1699748657

General Payments — all program years on this page

$1,206.06

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 44
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $482.54 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $482.5420

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Amgen Inc. $126.475
NOVARTIS PHARMACEUTICALS CORPORATION $97.364
Novo Nordisk AS $80.434
Lilly USA, LLC $60.262
PFIZER INC. $46.092
Astellas Pharma US Inc $27.361
Phadia US Inc. $25.491
ABBVIE INC. $19.081

By program year

Program yearAmountRecords
2021 $79.724
2022 $140.182
2023 $503.6218
2024 $482.5420

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1067583156 Phadia US Inc. $25.49 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087304839 Novartis Pharmaceuticals Corporation $22.18 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087304851 Novartis Pharmaceuticals Corporation $30.14 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087304855 Novartis Pharmaceuticals Corporation $26.69 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087304865 Novartis Pharmaceuticals Corporation $18.35 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100308201 Novo Nordisk Inc $18.22 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100331864 Novo Nordisk Inc $20.01 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100485143 Novo Nordisk Inc $21.39 10/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100537796 Novo Nordisk Inc $20.81 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1108246994 ABBVIE INC. $19.08 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117390694 Amgen Inc. $19.95 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117390696 Amgen Inc. $23.73 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117390698 Amgen Inc. $27.74 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117390700 Amgen Inc. $23.65 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117390702 Amgen Inc. $31.40 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131604423 PFIZER INC. $24.71 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131695322 PFIZER INC. $21.38 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135809413 Lilly USA, LLC $25.37 06/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135810991 Lilly USA, LLC $34.89 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139501284 Astellas Pharma US Inc $27.36 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.